Engineered Endolysin Program(s)
Drug-resistant bacterial infections (e.g., MRSA, P. aeruginosa)
PreclinicalActive
Key Facts
Indication
Drug-resistant bacterial infections (e.g., MRSA, P. aeruginosa)
Phase
Preclinical
Status
Active
Company
About Gangagen
GangaGen engineers bacteriophage-derived endolysin proteins to create targeted, novel antibiotics for drug-resistant bacterial infections.
View full company profile